Clinical Trial Update: Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial involving mTOR inhibitors and CMV-specific immune response in kidney transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections
• Kidney Transplantation

Snippet

Sponsor: Edoardo Melilli | Conditions: Kidney Transplantation, Cytomegalovirus Infections | Phase 4 | Status: WITHDRAWN